Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Treatment with delgocitinib 0.5% ointment leads to clinical improvements in adult patients with moderate-to-severe atopic dermatitis (AD) for up to 28 weeks, according to a Japan study.
Interim findings from the HELP/HELP OLE* studies presented at AAAAI 2020 have shown that the monoclonal antibody lanadelumab has the potential to reduce hereditary angioedema (HAE) attack rates.
Exposure to oral or topical terbinafine during pregnancy does not increase the risk of major malformations and spontaneous abortion, according to a recent study.
When it comes to protection against ultraviolet radiation–induced erythema and sunburn, sunscreen with sun protection factor (SPF) 100+ is significantly better than that with SPF 50+ in actual use at the beach, a recent study has shown.
The novel, high-affinity, monoclonal antibody lebrikizumab demonstrated significant efficacy in a dose-dependent manner across a range of clinical manifestations of moderate-to-severe atopic dermatitis (AD), including pruritus and quality of life (QoL), a phase IIb study has shown.
Use of the interleukin-31 receptor A monoclonal antibody nemolizumab significantly reduced the severity of pruritus in patients with moderate-to-severe prurigo nodularis, a phase II trial has shown.
Current algorithm-based smartphone apps show poor and variable performance in detecting all cases of melanoma or other skin cancer, a systematic review of diagnostic accuracy studies has found. Moreover, the existing assessment processes for awarding the Conformit Europenne (CE) marking for these apps are inadequate for protecting the public.
Special Reports
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Topical silicone gel is considered first-line therapy against scars and is used particularly for the treatment of elevated scars,such as hypertrophic and keloid scars. In this report, Dr Yong shares his clinical experience of using silicone gel as part of his scar management strategies.
Sunscreen products commonly contain only filters against ultraviolet (UV) radiation. At a recentdinner symposium organized by Eucerin, Dr Rungsima Wanitphakdeedecha discussed whythis is insufficient and what is required for effective protection against the damaging effects ofsunlight on the skin
In conjunction with the launch of QV Intensive with Ceramides (Ego Pharm), the important role of ceramides in themanagement of atopic dermatitis (AD) was highlighted by two distinguished speakers, Dr Agnes Heng of KPJ and Pantai Hospital Ipoh, as well as Dr Fabrizio Spada of Ego Pharmaceuticals, Australia.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
A wound is a disruption of the normal structure and function of the epidermis. Wounds maybe caused by acute traumatic injury to the skin, or other aetiologies that cause initially intact skin to break down. Recently, Dato’ Dr Ho Teik Kok shared his insights into the importance of micronutrients for wound recovery, stressing on the importance of treating the underlying diseases that may impede wound healing.
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Conference Reports
Patients with moderate-to-severe atopic dermatitis (AD) were more likely to have clinically meaningful responses when treated with dupilumab at doses of 300 mg either weekly or every 2 weeks compared with those on placebo, according to a post hoc analysis of the phase III SOLO 1 and SOLO 2* trials presented as a poster at AAD 2019.
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.
Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.
The novel Janus kinase (JAK) inhibitor delgocitinib exhibited favourable efficacy and safety for moderate-to-severe atopic dermatitis (AD), according to a phase III study presented at AAD 2019.
The benefits of the fully human monoclonal antibody secukinumab at doses of either 150 or 300 mg weekly in patients with active psoriatic arthritis are sustained even after 4 years, according to updated results of the FUTURE 2* study presented at the Inflammatory Skin Disease Summit (ISDS 2018).
Treatment with risankizumab, an interleukin-23 inhibitor, significantly improves skin appearance in patients with moderate-to-severe plaque psoriasis, according to the IMMvent* study presented at the Inflammatory Skin Disease Summit (ISDS).
